TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME b...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2024-10-01
|
| سلاسل: | Journal for ImmunoTherapy of Cancer |
| الوصول للمادة أونلاين: | https://jitc.bmj.com/content/12/10/e009613.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|